Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-fc79b24fd8d9aad3e2636eda8908eb2a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-fc79b24fd8d9aad3e2636eda8908eb2a"/>
<resource>
<Composition>
<id value="composition-en-fc79b24fd8d9aad3e2636eda8908eb2a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-fc79b24fd8d9aad3e2636eda8908eb2a"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-fc79b24fd8d9aad3e2636eda8908eb2a</b></p><a name="composition-en-fc79b24fd8d9aad3e2636eda8908eb2a"> </a><a name="hccomposition-en-fc79b24fd8d9aad3e2636eda8908eb2a"> </a><a name="composition-en-fc79b24fd8d9aad3e2636eda8908eb2a-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/98/080/001-002</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - aldara</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/98/080/001-002"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpfc79b24fd8d9aad3e2636eda8908eb2a"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - aldara"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Aldara cream is and what it is used for</li><li>What you need to know before you use Aldara cream</li><li>How to use Aldara cream</li><li>Possible side effects</li><li>How to store Aldara cream</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What aldara is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What aldara is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Aldara cream may be used for three different conditions. Your doctor may prescribe Aldara cream for the treatment of:</p><ul><li><p>Warts (condylomata acuminata) on the surface of the genitals (sexual organs) and around the anus (back passage)</p></li><li><p>Superficial basal cell carcinoma.<br/>This is a common slow-growing form of skin cancer with a very small likelihood of spread to other parts of the body. It usually occurs in middle-aged and elderly people, especially those who are fair-skinned and is caused by too much sun exposure. If left untreated, basal cell carcinoma can disfigure, especially on the face therefore early recognition and treatment are important.</p></li><li><p>Actinic keratosis Actinic keratoses are rough areas of skin found in people who have been exposed to a lot of sunshine over the course of their lifetime. Some are skin coloured, others are greyish, pink, red or brown. They can be flat and scaly, or raised, rough, hard and warty. Aldara should only be used for flat actinic keratoses on the face and scalp in patients with a healthy immune system where your doctor has decided that Aldara is the most appropriate treatment for you.</p></li></ul><p>Aldara cream helps your body s own immune system to produce natural substances which help fight your basal cell carcinoma, actinic keratosis or the virus that has caused your warts.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take aldara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take aldara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Aldara cream</p><ul><li>if you are allergic to imiquimod or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before using Aldara cream</p><ul><li>If you have previously used Aldara cream or other similar preparations tell your doctor before starting this treatment.</li><li>If you suffer from autoimmune disorders</li><li>If you have had an organ transplant</li><li>Do not use Aldara cream until the area to be treated has healed after previous drug or surgical treatment.</li><li>Avoid contact with the eyes, lips and nostrils. In the event of accidental contact, remove cream by rinsing with water.</li><li>Do not apply the cream internally.</li><li>Do not use more cream than your doctor has advised.</li><li>Do not cover the treated area with bandages or other dressings after you have applied Aldara cream.</li><li>If the treated site becomes too uncomfortable, wash the cream off with mild soap and water. As soon as the problem has stopped you may restart to apply the cream.</li><li>Tell your doctor if you have an abnormal blood count.</li></ul><p>Because of the way Aldara works, there is a possibility that the cream may worsen existing inflammation in the treatment area.</p><ul><li>If you are being treated for genital warts follow these additional precautions:</li></ul><p>Men with warts under the foreskin should pull the foreskin back each day and wash underneath it. If not washed daily the foreskin may be more likely to show signs of tightness, swelling and wearing away of the skin and result in difficulty in pulling it back. If these symptoms occur, stop the treatment immediately and call your doctor. If you have open sores: do not start using Aldara cream until after the sores have healed. If you have internal warts: do not use Aldara cream in the urethra (the hole from which urine is passed), the vagina (birth canal), the cervix (internal female organ), or anywhere inside your anus (rectum). Do not use this medication for more than one course if you have problems with your immune system, either due to illness or because of the medicines you are already taking. If you think this applies to you talk to your doctor. If you are HIV positive you should inform your doctor as Aldara cream has not been shown to be as effective in HIV positive patients.<br/>If you decide to have sexual relations while you still have warts, apply Aldara cream after - not before - sexual activity. Aldara cream may weaken condoms and diaphragms, therefore the cream should not be left on during sexual activity. Remember, Aldara cream does not protect against giving HIV or other sexually transmitted diseases to someone else.</p><ul><li>If you are being treated for basal cell carcinoma or actinic keratosis follow these additional precautions:</li></ul><p>Do not use sunlamps or tanning beds, and avoid sunlight as much as possible during treatment with Aldara cream. Wear protective clothing and wide brimmed hats when outdoors.</p><p>Whilst using Aldara cream and until healed, the treatment area is likely to appear noticeably different from normal skin.</p><p>Children and adolescents</p><p>Use in children and adolescents is not recommended.</p><p>Other medicines and Aldara cream</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are no medicines known to be incompatible with Aldara cream.</p><p>Pregnancy and breast-feeding</p><p>Ask your doctor or pharmacist for advice before taking any medicine. You must tell your doctor if you are pregnant or intend to become pregnant. Your doctor will discuss the risks and benefits of using Aldara cream during pregnancy. Studies in animals do not indicate direct or indirect harmful effects in pregnancy.</p><p>Do not breast-feed your infant during treatment with Aldara cream, as it is not known whether imiquimod is secreted in human milk.</p><p>Driving and using machines</p><p>This medicine has no or negligible influence on the ability to drive and use machines.</p><p>Aldara cream contains methyl hydroxybenzoate, propyl hydroxybenzoate, cetyl alcohol, stearyl alcohol and benzyl alcohol</p><p>Methyl hydroxybenzoate (E 218) and propyl hydroxybenzoate (E 216) may cause allergic reactions (possibly delayed). Cetyl alcohol and stearyl alcohol may cause local skin reactions (e.g. contact dermatitis). This medicine contains 5 mg benzyl alcohol in each sachet. Benzyl alcohol may cause allergic reactions and mild local irritation.</p></div>
</text>
</section>
<section>
<title value="3. How to take aldara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take aldara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Children and adolescents: Use in children and adolescents is not recommended.</p><p>Adults: Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br/>Wash hands carefully before and after applying the cream. Do not cover the treated area with bandages or other dressings after you have applied Aldara cream. Open a new sachet each time you use the cream. Dispose of any cream left in the sachet after use. Do not save the opened sachet for use at a later date.</p><p>The treatment frequency and duration differ for genital warts, basal cell carcinoma and actinic keratosis (see specific instructions for each indication).</p><ul><li>If you are being treated for genital warts:</li></ul><p>Application Instructions (Mon, Wed and Fri)</p><ol type="1"><li>Before going to bed, wash your hands and the treatment area with mild soap and water. Dry thoroughly.</li><li>Open a new sachet and squeeze some cream onto your fingertip.</li><li>Apply a thin layer of Aldara cream onto clean, dry wart area and rub gently into the skin until cream vanishes.</li><li>After application of the cream, throw away the opened sachet and wash hands with soap and water.</li><li>Leave Aldara cream on the warts for 6 to 10 hours. Do not shower or bathe during this time.</li><li>After 6 to 10 hours wash the area where Aldara cream was applied with mild soap and water.</li></ol><p>Apply Aldara cream 3 times per week. For example, apply the cream on Monday, Wednesday and Friday. One sachet contains enough cream to cover a wart area of 20 cm2 (approx. 3 square inches).</p><p>Men with warts under the foreskin should pull the foreskin back each day and wash underneath it (see section 2 Warnings and precautions )</p><p>Continue to use Aldara cream as instructed until your warts have completely gone (half the females who clear will do so in 8 weeks, half the males who clear will do so in 12 weeks but in some patients warts may clear as early as 4 weeks).</p><p>Do not use Aldara cream for more than 16 weeks in the treatment of each episode of warts.</p><p>If you have the impression that the effect of Aldara cream is too strong or too weak, talk to your doctor or pharmacist.</p><ul><li>If you are being treated for basal cell carcinoma:</li></ul><p>Application Instructions (Mon, Tues, Wed, Thurs and Fri)</p><ol type="1"><li>Before going to bed, wash your hands and the treatment area with mild soap and water. Dry thoroughly.</li><li>Open a new sachet and squeeze some cream onto your fingertip.</li><li>Apply Aldara cream to the affected area and 1cm (approx. 0.5 inch) around the affected area. Rub gently into the skin until the cream vanishes.</li><li>After application of the cream, throw away the opened sachet. Wash hands with soap and water.</li><li>Leave Aldara cream on the skin for about 8 hours. Do not shower or bathe during this time.</li><li>After about 8 hours, wash the area where Aldara cream was applied with mild soap and water.</li></ol><p>Apply sufficient Aldara cream to cover the treatment area and 1 cm (about an inch) around the treatment area each day for 5 consecutive days each week for 6 weeks. For example, apply the cream from Monday to Friday. Do not apply the cream on Saturday and Sunday.</p><ul><li>If you are being treated for actinic keratosis</li></ul><p>Application Instructions (Mon, Wed and Fri)</p><ol type="1"><li>Before going to bed, wash your hands and the treatment area with mild soap and water. Dry thoroughly.</li><li>Open a new sachet and squeeze some cream onto your fingertip.</li><li>Apply the cream to the affected area. Rub gently into the area until the cream vanishes.</li><li>After application of the cream, throw away the opened sachet. Wash hands with soap and water.</li><li>Leave Aldara cream on the skin for about 8 hours. Do not shower or bathe during this time.</li><li>After about 8 hours, wash the area where Aldara cream was applied with mild soap and water.</li></ol><p>Apply Aldara cream 3 times per week. For example, apply the cream on Monday, Wednesday and Friday. One sachet contains enough cream to cover an area of 25 cm2 (approx. 4 square inches). Continue treatment for four weeks. Four weeks after finishing this first treatment, your doctor will</p><p>assess your skin. If the lesions have not all disappeared, further four weeks of treatment may be necessary.</p><p>If you use more Aldara cream than you should</p><p>Wash the extra away with mild soap and water. When any skin reaction has gone you may then continue with your treatment.</p><p>If you accidentally swallow Aldara cream please contact your doctor.</p><p>If you forget to use Aldara cream</p><p>If you miss a dose, apply cream as soon as you remember and then continue in your regular schedule. Do not apply the cream more than once per day.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The frequency of side effects is classified as follows:<br/>Very common side effects (likely to occur in more than 1 in 10 patients) Common side effects (likely to occur in fewer than 1 in 10 patients) Uncommon side effects (likely to occur in fewer than 1 in 100 patients) Rare side effects (likely to occur in fewer than 1 in 1,000 patients) Very rare side effects (likely to occur in fewer than 1 in 10,000 patients).</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using Aldara cream.<br/>Some patients have experienced changes in skin colour in the area where Aldara cream was applied. While these changes have tended to improve with time, in some patients they may be permanent. If your skin reacts badly when using Aldara cream, stop applying the cream, wash the area with mild soap and water and contact your doctor or pharmacist.<br/>In some individuals a lowering of blood counts was noted. A lowering of blood counts might make you more susceptible to infections, make you bruise more easily or cause fatigue. If you notice any of these symptoms, tell your doctor. Some patients who suffer from autoimmune disorders may experience worsening of their condition. If you notice any change during treatment with Aldara cream, tell your doctor. Serious skin reactions have been reported rarely. If you experience skin lesions or spots on your skin that start out as small red areas and progress to look like mini targets, possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores, stop using Aldara cream and tell your doctor immediately. A small number of patients have experienced hair loss at the treatment site or surrounding area.</p><p>If you are being treated for genital warts:</p><p>Many of the undesirable effects of Aldara cream are due to its local action on your skin.</p><p>Very common effects include redness (61% patients), wearing away of the skin (30% patients), flakiness and swelling. Hardening under the skin, small open sores, a crust that forms during healing, and small bubbles under the skin may also occur. You might also feel itching (32% patients), a burning sensation (26% patients) or pain in areas where you have applied Aldara cream (8% patients). Most of these skin reactions are mild and the skin will return to normal within about 2 weeks after stopping treatment.</p><p>Commonly some patients (4% or less) have experienced headache, uncommonly fevers and flu like symptoms joint and muscle pains; prolapse of the womb; pain on intercourse in females; erection difficulties; increase in sweating; feeling sick; stomach and bowel symptoms; ringing in the ears; flushing; tiredness; dizziness; migraine; pins and needles; insomnia; depression; loss of appetite; swollen glands; bacterial, viral and fungal infections (e.g. cold sores); vaginal infection including thrush; cough and colds with sore throat.</p><p>Very rarely severe and painful reactions have occurred, particularly when more cream has been used than recommended. Painful skin reactions at the opening of the vagina have very rarely made it difficult for some women to pass urine. If this occurs you should seek medical help immediately.</p><p>If you are being treated for basal cell carcinoma:</p><p>Many of the undesirable effects of Aldara cream are due to its local action on your skin. Local skin reactions can be a sign that the drug is working as intended.</p><p>Very Commonly the treated skin may be slightly itchy.</p><p>Common effects include: pins and needles, small swollen areas in the skin, pain, burning, irritation, bleeding, redness or rash.<br/>If a skin reaction becomes too uncomfortable during treatment, speak to your doctor. He/she may advise you to stop applying Aldara cream for a few days (i.e. to have a short rest from treatment).<br/>If there is pus (matter) or other suggestion of infection, discuss this with your doctor. Apart from reactions in the skin, other common effects include swollen glands and back pain. Uncommonly some patients experience changes at the application site (discharge, inflammation, swelling, scabbing, skin breakdown, blisters, dermatitis) or irritability, feeling sick, dry mouth, flu-like symptoms and tiredness.</p><p>If you are being treated for actinic keratosis</p><p>Many of the undesirable effects of Aldara cream are due to its local action on your skin. Local skin reactions can be a sign that the drug is working as intended.</p><p>Very commonly the treated skin may be slightly itchy.</p><p>Common effects include pain, burning, irritation or redness.<br/>If a skin reaction becomes too uncomfortable during treatment, speak to your doctor. He/she may advise you to stop applying Aldara cream for a few days (i.e. to have a short rest from treatment). If there is pus (matter) or other suggestion of infection, discuss this with your doctor. Apart from reactions in the skin, other common effects include headache, anorexia, nausea, muscle pain, joint pain and tiredness.</p><p>Uncommonly some patients experience changes at the application site (bleeding, inflammation, discharge, sensitivity, swelling, small swollen areas in the skin, pins and needles, scabbing, scarring, ulceration or a feeling of warmth or discomfort), or inflammation of the lining of the nose, stuffy nose, flu or flu-like symptoms, depression, eye irritation, swelling of the eyelid, throat pain, diarrhoea, actinic keratosis, redness, swelling of the face, ulcers, pain in extremity, fever, weakness or shivering.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store aldara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store aldara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 25 C.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and the label after EXP.</p><p>Sachets should not be re-used once opened.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Aldara cream contains</p><ul><li>The active substance is imiquimod. Each sachet contains 250 mg cream (100 mg cream contains 5 mg imiquimod).</li><li>The other ingredients are isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, white soft paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate (E 218), propyl hydroxybenzoate (E 216), xanthan gum, purified water (see also section 2 Aldara cream contains methyl hydroxybenzoate, propyl hydroxybenzoate, cetyl alcohol, stearyl alcohol and benzyl alcohol ).</li></ul><p>What Aldara cream looks like and contents of the pack</p><ul><li>Each Aldara 5% cream sachet contains 250 mg of a white to slightly yellow cream.</li><li>Each box contains 12 or 24 single-use polyester/aluminium foil sachets. Not all pack sizes may</li></ul><p>be marketed.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorisation Holder Viatris Healthcare Limited Damastown Industrial Park Mulhuddart Dublin DUBLIN Ireland</p><p>Manufacturer Swiss Caps GmbH Grassingerstra e 9 83043 Bad Aibling Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>Belgi /Belgique/Belgien Viatris<br/>T l/Tel: +32 2 658 61 Luxembourg/Luxemburg Viatris<br/>T l/Tel: +32 2 658 61 (Belgique/Belgien)</p><p>.: +359 2 44 55 Magyarorsz g Viatris Healthcare Kft. 1138 Budapest V ci t 150. Tel: +36 1 465 2 esk republika Viatris CZ s.r.o. Tel: +420 222 004 Malta V.J. Salomone Pharma Limited Upper Cross Road Marsa, MRS 1Tel: +356 21 22 01 Danmark Viatris ApS Tlf: +45 28 11 69 Nederland Mylan Healthcare B.V. Krijgsman 1186 DM Amstelveen Tel: +31 (0)20 426 3Deutschland Viatris Healthcare GmbH Tel: +49 800 0700 Norge Viatris AS<br/>Hagal kkveien 1383 Asker Tlf: +47 66 75 33 Eesti Viatris O<br/>Tel: +372 63 63 sterreich Viatris Austria GmbH Guglgasse 1110 Wien Tel: + 43 (0)1 86<br/>Viatris Hellas Ltd : +30 210 010 0Polska Viatris Healthcare Sp. z o.o. ul. Post pu 21B 02-676 Warszawa Tel: +48 22 546 6Espa a Viatris Pharmaceuticals, S.L. Tel: +34 900 102 Portugal Viatris Healthcare, Lda. Av. D. Jo o II,<br/>Edif cio Atlantis, n 44C 7.3 e 7.4 1990-095 Lisboa Tel: +351 214 127 France Viatris Sant<br/>1 bis place de la D fense Tour Trinity 92400 Courbevoie T l: +33 (0)1 40 80 15 Rom nia BGP PRODUCTS SRL Tel.: +40372 579 Hrvatska Viatris Hrvatska d.o.o. Koranska 2 10 000 Zagreb Tel: +385 1 2350 Slovenija Viatris d.o.o. Tel: +386 1 23 63 Ireland Mylan Ireland Limited Tel: +353 1 8711Slovensk republika Viatris Slovakia s.r.o. Tel: +421 2 32 199 sland Icepharma hf. S mi: +354 540 8Suomi/Finland Viatris Oy Vaisalantie 2-8/Vaisalav gen 2-8 02130 Espoo/Esbo Puh/Tel: +358 20 720 9Italia Viatris Italia Via Vittor Pisani, 20124 Milano Tel: +39 0261246Sverige Viatris AB Box 23104 35 Stockholm +46 (0) 8 630 19<br/>GPA Pharmaceuticals Ltd : +357 22863United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited Tel: +353 18711Latvija Viatris SIA 101 M kusalas str. R ga LV 1T lr: +371 67616Lietuva Viatris UAB algirio str. 90-Vilnius LT-09Tel. + 370 52051This leaflet was last revised in (MM/YYYY).</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpfc79b24fd8d9aad3e2636eda8908eb2a"/>
<resource>
<MedicinalProductDefinition>
<id value="mpfc79b24fd8d9aad3e2636eda8908eb2a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpfc79b24fd8d9aad3e2636eda8908eb2a"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpfc79b24fd8d9aad3e2636eda8908eb2a</b></p><a name="mpfc79b24fd8d9aad3e2636eda8908eb2a"> </a><a name="hcmpfc79b24fd8d9aad3e2636eda8908eb2a"> </a><a name="mpfc79b24fd8d9aad3e2636eda8908eb2a-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/98/080/001-002</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: ALDARA 5% cream</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/98/080/001-002"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="ALDARA 5% cream"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
